Drug Type Small molecule drug |
Synonyms HEMAY 022 |
Target |
Mechanism HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationSpecial Review Project (CN) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced breast cancer | Phase 3 | CN | 08 Jan 2022 | |
ER-positive/HER2-positive Breast Cancer | Phase 3 | CN | 08 Jan 2022 | |
HER2 Positive Breast Cancer | Phase 1 | CN | 10 Jul 2019 | |
HER2 Positive Breast Cancer | Phase 1 | CN | 10 Jul 2019 | |
Advanced HER2-Positive Breast Carcinoma | Phase 1 | CN | 14 Oct 2015 |
Phase 1 | Metastatic human epidermal growth factor 2 positive carcinoma of breast estrogen receptor-positive | HER2+ | 55 | Sacibertinib plus endocrine therapy | lvhcxejmbi(zfcygofusc) = 9.1% lwlledcbfu (wgkqiilbkk ) View more | Positive | 05 Dec 2023 | |
Phase 1 | Metastatic human epidermal growth factor 2 positive carcinoma of breast estrogen receptor-positive | HER2-positive | 55 | Sacibertinib (Hemay022) plus endocrine therapy | osgdulhedo(celoocpzjn) = tvenprkaih laoaiiajiq (uqnclcgmmw, 5.5 - 11.0) | Positive | 05 Dec 2023 | |
Phase 1 | Metastatic human epidermal growth factor 2 positive carcinoma of breast estrogen receptor-positive | HER2-positive | 55 | Sacibertinib (Hemay022) plus endocrine therapy | sjljjtunjf(vbrbhwozjt) = opklrhtylc zzedoqldbs (zdgoloksez, 5.5 - 11.0) | Positive | 15 Oct 2021 | |
Phase 1 | Metastatic human epidermal growth factor 2 positive carcinoma of breast estrogen receptor-positive | HER2+ | 55 | Sacibertinib plus endocrine therapy | hixfysiqlm(imsoyajjtv) = 9.1% habifvozsh (ximsekxjxy ) View more | Positive | 01 Jul 2021 |